Maxim Group analyst Jason McCarthy maintained a Buy rating on Inovio Pharmaceuticals (INO) today and set a price target of $8. The company’s shares opened today at $5.02.
McCarthy observed:
“Inovio announced that a second patient with HPV-related head and neck cancer (HNC), treated with MEDI0457 (Inovio’s INO-3112 synthetic DNA vaccine), achieved a sustained complete response (CR) following subsequent treatment with the PD-1 checkpoint inhibitor Keytruda. The data were presented at this year’s Keystone Symposia Conference/Cancer Vaccines. The first patient, reported last October, achieved a CR with MEDI0457 and the checkpoint inhibitor Opdivo.”
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -8.0% and a 28.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on Inovio Pharmaceuticals is a Moderate Buy with an average price target of $10.50, a 109.2% upside from current levels. In a report issued on January 16, H.C. Wainwright also reiterated a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
Based on Inovio Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $25.02 million. In comparison, last year the company had a GAAP net loss of $21.51 million.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2018, Avtar Dhillon, a Director at INO bought 25,000 shares for a total of $50,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
